These guides are AI-generated educational summaries — not legal or medical advice.
C&P Exam Prep: Bone Cancer (Malignant Bone Neoplasm)
DBQ Overview
Interview + Physical- Form Name
- Bones_and_Other_Skeletal_Conditions
- Form Code
- Bones_and_Other_Skeletal_Conditions
- Page Count
- 7
- Examiner Type
- Orthopedic Surgeon, Oncologist, or appropriate clinician
- Estimated Duration
- 30-45 minutes
- Exam Format
- Interview + Physical
What to Expect During Your Exam
Exam Overview
To document the diagnosis, treatment status, residuals, functional impairment, and overall severity of a malignant bone neoplasm (primary or secondary/metastatic) for VA disability rating purposes under Diagnostic Code 5012.
What the examiner evaluates:
- Confirmed diagnosis of malignant bone neoplasm (primary or secondary/metastatic) with ICD code
- Whether the cancer is active or in remission
- Whether the cancer is primary or secondary (metastatic) and, if secondary, the primary site
- Current treatment status: surgery, radiation therapy, antineoplastic chemotherapy, other therapeutic treatment, or completed treatment
- Dates of most recent and anticipated completion of treatment
- Residuals and complications of the malignancy and/or treatment (e.g., pathologic fractures, limb loss, functional limitations, peripheral neuropathy, lymphedema)
- Functional impact on daily activities and occupational functioning
- Assistive devices used (wheelchair, crutches, canes, walker, braces) and frequency of use
- Affected extremities and body regions (right upper, left upper, right lower, left lower)
- Presence of surgical scars or disfigurement
- Imaging study results (bone scan, X-ray, MRI, CT) and biopsy/culture findings
- Additional diagnoses pertaining to bones or neoplasms
- Impact on remaining function of affected and adjacent structures
The exam may be conducted in person at a VA facility, VAMC, or contracted examiner clinic (e.g., LHI, QTC, VES). Telehealth or records-review exams may occur in some circumstances. If conducted other than in person, the examiner must document how the exam was conducted. Active cancer with treatment toxicity may affect your ability to travel; note any such limitations to your VSO when scheduling.
Typical duration: 30-45 minutes
Bone Scan (Scintigraphy)
Extent of bone involvement, presence of metastatic lesions, and disease activity throughout the skeletal system.
What to expect:
Review of existing bone scan imaging; examiner will note date of test and results. Bring copies of any recent bone scans to the exam.
Key thresholds:
- Active lesion(s) present — Supports active malignancy rating; may warrant 100% while active
- No active lesions / clear scan — May support remission status; rating based on residuals thereafter
Tips:
- Bring copies of all imaging reports including dates and interpreting radiologist notes.
- If multiple scans exist, bring the most recent and any that show the worst disease burden.
- Clearly state if your bone scan showed new or worsening lesions since last evaluation.
Pain considerations: Bone scan results often correlate with pain locations; be prepared to describe bone pain at each site identified on imaging.
MRI (Magnetic Resonance Imaging)
Soft tissue involvement, tumor size and extent, marrow infiltration, and nerve or vascular involvement by the neoplasm.
What to expect:
Examiner reviews existing MRI reports. Bring printed or digital copies of all relevant MRI reports with dates.
Key thresholds:
- Tumor involvement of adjacent structures — Supports higher severity rating and documents complications
- Post-treatment changes without active tumor — Supports remission; residual scarring or fibrosis still rated
Tips:
- Note which body part the MRI covered and the date of each study.
- If MRI shows nerve or vascular involvement, mention any resulting numbness, weakness, or circulatory symptoms.
Pain considerations: MRI findings of marrow edema or cortical destruction correlate with severe bone pain; describe pain severity at those specific anatomical sites.
X-Ray (Plain Radiograph)
Bone destruction, pathologic fractures, periosteal reaction, calcification, and structural integrity of affected bones.
What to expect:
Examiner reviews existing X-ray reports. Lytic or blastic lesions, pathologic fractures, and post-surgical hardware will be noted.
Key thresholds:
- Pathologic fracture identified — Significant complication supporting higher functional impairment rating
- Cortical destruction present — Indicates active or aggressive disease; supports severe rating
Tips:
- Bring all X-ray reports including pre- and post-treatment films if available.
- If you have had pathologic fractures, document the date, location, treatment, and whether full healing occurred.
Pain considerations: X-ray evidence of bone destruction often underrepresents pain severity; verbally describe pain intensity even if imaging appears improved.
Bone Biopsy and/or Culture
Histological confirmation of malignancy type (e.g., osteosarcoma, chondrosarcoma, Ewing sarcoma, metastatic carcinoma), grade, and extent.
What to expect:
Examiner reviews biopsy pathology reports. This is the definitive diagnostic confirmation of malignancy.
Key thresholds:
- Confirmed malignant histology — Required for DC 5012 rating; establishes diagnosis for VA purposes
- High-grade malignancy — Supports aggressive treatment course and more severe functional limitations
Tips:
- Bring pathology reports from biopsy including the pathologist's interpretation.
- Note the tumor type, grade, and any molecular markers documented in the report.
Pain considerations: Biopsy sites may themselves be a source of residual pain; mention this if applicable.
Range of Motion (ROM) Assessment
Functional limitation of joints and limbs adjacent to or affected by the malignant bone neoplasm or its treatment (surgery, radiation).
What to expect:
Examiner will measure active and passive ROM of affected joints using a goniometer. Weight-bearing and non-weight-bearing assessments may be performed per Correia requirements. DeLuca factors (pain, fatigue, weakness, incoordination, flare-ups, repetitive use) must be considered.
Key thresholds:
- Significant ROM limitation due to tumor or surgical resection — May support rating under analogous musculoskeletal DCs in addition to DC 5012
- Complete functional loss of a limb — May support amputation or complete ankylosis rating
Tips:
- Demonstrate your true, pain-limited range of motion - do not push through pain to show a wider range.
- Inform the examiner if ROM worsens after repetitive use or later in the day (DeLuca factor).
- Mention if ROM is worse on flare-up days versus your current presentation.
- If weight-bearing causes pain or is impossible, state this clearly.
Pain considerations: Pain with motion should be described in terms of location, quality, severity (0-10 scale), and whether it stops you from completing the motion. Report pain at rest, with movement, and after activity.
Rating Criteria Breakdown
| Rating % | Criteria | Key Symptoms |
|---|---|---|
| 100% | Active malignant neoplasm of bone. Under 38 CFR 4.71a DC 5012 and general VA policy (38 CFR 4.29 / 4.30), an active malignancy warrants a 100% rating while the cancer is active and for a period following treatment completion (typically a minimum of six months after the cessation of surgical, radiation, or antineoplastic chemotherapy treatment). After that period, the rating is based on documented residuals. |
CFR: 38 CFR 4.29 provides for a 100% rating for a period of six months following the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedures. After the six-month period, the rating is based on residuals. 38 CFR 4.30 addresses disability from surgery or treatment that is more disabling than the condition itself during convalescence. |
| 100% | Post-treatment period (38 CFR 4.29): 100% rating is maintained for a minimum of six months following the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic treatment for malignant neoplasm. During this period, even if the cancer is technically in remission, the 100% rating applies. |
CFR: 38 CFR 4.29: A 100% evaluation will be assigned from the date of onset of the incapacitating episode or from the date of hospital admission for treatment, continuing for a period of six months from the date the treatment was discontinued, at which time the appropriate disability rating will be determined by mandatory VA examination. |
| 0% | Post-treatment residual evaluation: After the mandatory six-month post-treatment period (or longer if treatment is ongoing), the rating is based on documented residuals of the malignancy and/or treatment. Residuals are rated under the most appropriate diagnostic code for the resulting condition (e.g., limited motion of joint, amputation, nerve damage, lymphedema). A 0% (non-compensable) rating is assigned only if residuals are present but do not meet the threshold for a compensable rating under the applicable code. No rating below 10% should be assigned if any compensable residual exists. |
CFR: After the six-month post-treatment evaluation period, VA must rate the veteran based on the actual residuals present. If no compensable residuals exist, a 0% rating may apply, but service connection should still be established to protect future claims. |
100% Active malignant neoplasm of bone. Under 38 CFR 4.71a DC 501 ...
Active malignant neoplasm of bone. Under 38 CFR 4.71a DC 5012 and general VA policy (38 CFR 4.29 / 4.30), an active malignancy warrants a 100% rating while the cancer is active and for a period following treatment completion (typically a minimum of six months after the cessation of surgical, radiation, or antineoplastic chemotherapy treatment). After that period, the rating is based on documented residuals.
Key Symptoms
- Active malignant bone tumor confirmed by biopsy or imaging
- Ongoing surgical, chemotherapy, or radiation treatment
- Systemic symptoms: fatigue, weight loss, fever, night sweats
- Severe pain requiring opioid or strong analgesic management
- Pathologic fractures
- Significant functional loss of affected limb or body region
- Metastatic spread to additional sites
- Hospitalization or frequent oncology appointments required
CFR: 38 CFR 4.29 provides for a 100% rating for a period of six months following the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedures. After the six-month period, the rating is based on residuals. 38 CFR 4.30 addresses disability from surgery or treatment that is more disabling than the condition itself during convalescence.
100% Post-treatment period (38 CFR 4.29): 100% rating is maintain ...
Post-treatment period (38 CFR 4.29): 100% rating is maintained for a minimum of six months following the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic treatment for malignant neoplasm. During this period, even if the cancer is technically in remission, the 100% rating applies.
Key Symptoms
- Recently completed surgery, chemotherapy, or radiation therapy
- Treatment-related toxicities: neuropathy, fatigue, immunosuppression, anemia
- Post-surgical recovery limiting function
- Radiation-induced tissue damage or fibrosis
- Ongoing pain management requirements
- Chemotherapy side effects impacting daily function
CFR: 38 CFR 4.29: A 100% evaluation will be assigned from the date of onset of the incapacitating episode or from the date of hospital admission for treatment, continuing for a period of six months from the date the treatment was discontinued, at which time the appropriate disability rating will be determined by mandatory VA examination.
0% Post-treatment residual evaluation: After the mandatory six- ...
Post-treatment residual evaluation: After the mandatory six-month post-treatment period (or longer if treatment is ongoing), the rating is based on documented residuals of the malignancy and/or treatment. Residuals are rated under the most appropriate diagnostic code for the resulting condition (e.g., limited motion of joint, amputation, nerve damage, lymphedema). A 0% (non-compensable) rating is assigned only if residuals are present but do not meet the threshold for a compensable rating under the applicable code. No rating below 10% should be assigned if any compensable residual exists.
Key Symptoms
- Mild residual pain at tumor site managed with OTC medication
- Minimal range of motion limitation not meeting compensable threshold
- Resolved pathologic fracture with full healing and no functional loss
- Imaging showing no active disease and no structural compromise
CFR: After the six-month post-treatment evaluation period, VA must rate the veteran based on the actual residuals present. If no compensable residuals exist, a 0% rating may apply, but service connection should still be established to protect future claims.
How to Describe Your Symptoms
Bone Pain (Primary Symptom)
How to describe:
Describe the location of bone pain using anatomical terms (e.g., 'deep aching pain in my right femur,' 'sharp stabbing pain at the site of my tumor in my left tibia'). Rate pain on a 0-10 scale. Describe pain at rest, with movement, at night, and after activity. Note whether pain wakes you from sleep.
Worst-day example:
“On my worst days, the pain in my right femur is a 9/10 constant aching that radiates down to my knee. I cannot put any weight on the leg, I cannot sleep through the night, and I require narcotic pain medication every 4-6 hours just to get out of bed. I cannot walk more than 10 feet without stopping due to pain.”
What the examiner listens for:
Severity and quality of pain, pain at rest vs. activity, nocturnal pain (hallmark of malignant bone pain), pain limiting weight-bearing, pain requiring prescription analgesics, pain pattern consistent with tumor location on imaging.
Understatements to avoid:
Do not say 'the pain is manageable' without qualifying that it is only manageable WITH medication. Do not say 'it's not that bad today' - the examiner rates your overall condition, not just how you feel at that moment. Report your typical and worst-day experience.
Functional Limitation and Mobility
How to describe:
Describe specific activities you can no longer do or can only do with difficulty or pain: walking distances, climbing stairs, lifting, carrying, bending, sitting or standing for extended periods. Quantify limitations (e.g., 'I can only walk one block before I must stop,' 'I cannot climb stairs without a railing and must go one step at a time').
Worst-day example:
“On my worst days I am entirely bed-bound. I cannot dress myself without assistance. I cannot walk to the bathroom without my walker, and even then the pain is an 8/10. I cannot drive. I have not been able to work since my diagnosis.”
What the examiner listens for:
Impact on activities of daily living (ADLs), ability to ambulate, need for assistive devices, limitation of affected extremities, inability to perform occupational duties, dependence on others for care.
Understatements to avoid:
Do not minimize your mobility limitations by demonstrating abilities during the exam that you cannot sustain. If the examiner sees you walk into the room without a cane but you normally require one, clarify that you brought it but were trying not to seem dramatic. Always bring and use your actual assistive devices.
Treatment Side Effects and Toxicities
How to describe:
Describe specific side effects from chemotherapy (nausea, vomiting, fatigue, peripheral neuropathy, hair loss, immunosuppression, infections), radiation (local tissue damage, fibrosis, radiation necrosis, skin changes), or surgery (wound complications, functional loss, phantom limb pain if amputation occurred).
Worst-day example:
“During my chemotherapy cycles, I was bedridden for 5-7 days after each infusion. I lost 25 pounds, had severe peripheral neuropathy in both hands and feet making it impossible to button my shirt or walk without stumbling, and required hospitalization twice for febrile neutropenia. Even now that treatment is complete, the neuropathy in my feet has not resolved and I fall frequently.”
What the examiner listens for:
Specific treatment modalities received, toxicity grade, lasting versus resolved side effects, hospitalizations related to treatment, impact on function during and after treatment, treatment dates relative to the six-month post-treatment rating clock.
Understatements to avoid:
Do not omit treatment side effects because you think they are 'expected' or 'temporary.' All treatment-related impairments are relevant to the rating. Document every hospitalization, every ER visit, and every dose reduction or treatment delay caused by side effects.
Pathologic Fractures and Structural Complications
How to describe:
If you have had pathologic fractures (fractures caused by the tumor weakening the bone rather than by trauma), describe the location, date, how it was discovered, treatment (surgery, casting, radiation), and whether it healed completely. Describe any ongoing instability, deformity, or pain at the fracture site.
Worst-day example:
“My right humerus fractured spontaneously while I was simply reaching for a glass of water - no fall, no trauma. I was hospitalized, had surgery with an intramedullary rod placed, and still have significant pain and weakness in that arm 18 months later. I cannot lift more than 2 pounds with that arm and cannot raise it above shoulder height.”
What the examiner listens for:
Pathologic fracture history, surgical intervention required, completeness of healing on imaging, residual deformity or instability, functional loss attributable to the fracture, evidence of non-union or malunion.
Understatements to avoid:
Do not fail to mention pathologic fractures. They are a major complication that significantly affects rating. Even if the fracture 'healed,' residual pain and weakness are ratable residuals.
Fatigue and Systemic Symptoms (DeLuca Factor)
How to describe:
Describe cancer-related fatigue as distinct from normal tiredness: unrelenting exhaustion that is not relieved by rest, inability to complete tasks you start, need to rest multiple times during simple activities. Note fatigue from both the cancer itself and from treatment.
Worst-day example:
“On my worst days, I wake up exhausted after 10 hours of sleep. I can be showered and dressed by 9am and then need to lie down for 2 hours. I cannot cook a meal, do laundry, or go to a medical appointment on the same day. The fatigue is separate from the pain - even when pain is controlled, I am simply too exhausted to function.”
What the examiner listens for:
Whether fatigue limits the veteran's ability to perform repetitive use tasks (DeLuca factor), how quickly fatigue sets in with activity, whether fatigue is improving or worsening, cancer-related fatigue versus treatment-related fatigue.
Understatements to avoid:
Do not say 'I get tired sometimes.' Quantify: how many hours per day can you be active? How many rest periods do you need? Can you work a full day? Can you complete a single errand without resting?
Flare-Ups (DeLuca Factor)
How to describe:
Describe episodes when your symptoms are significantly worse than usual. Include frequency (how often do flare-ups occur?), duration (how long do they last?), severity during flare-ups (pain score, mobility loss), and what triggers them (activity, weather, stress, tumor progression).
Worst-day example:
“I have flare-ups of severe bone pain approximately 2-3 times per week that last 4-8 hours each. During these episodes my pain goes from a baseline of 5/10 to a 9-10/10. I cannot walk, I vomit from the pain, and I require breakthrough narcotic medication. These flare-ups have sent me to the ER twice in the last year.”
What the examiner listens for:
Frequency and duration of flare-ups, severity during flare-ups compared to baseline, triggers for flare-ups, whether flare-ups result in emergency care or hospitalization, impact on the veteran's ability to plan activities or work.
Understatements to avoid:
Do not assume flare-ups are irrelevant because you are not experiencing one at the time of the exam. The examiner must rate your overall condition including flare-up frequency and severity. State explicitly: 'Right now I am having a relatively better day. Let me describe what a bad day looks like.'
Remission Status and Fear of Recurrence
How to describe:
If your cancer is in remission, clearly state when remission was confirmed, what monitoring is ongoing (follow-up scans, labs, oncology appointments), and whether you have any residual symptoms from the cancer or its treatment. Also note any psychological impact such as cancer-related anxiety.
Worst-day example:
“My cancer has been in remission for 14 months, but I remain under active oncology surveillance with bone scans every three months. I still have daily pain at the surgical site rated 4-5/10, persistent peripheral neuropathy in both feet that causes me to fall, and I am unable to return to my pre-cancer occupation as a construction worker due to bone fragility and balance problems.”
What the examiner listens for:
Date of remission confirmation, ongoing monitoring regimen, residual symptoms post-remission, whether treatment-related disabilities persist, and occupational or social functioning after remission.
Understatements to avoid:
Do not say 'I am in remission so I am fine.' Remission does not mean no disability. All residuals of the cancer and its treatment remain ratable. Clearly document every persistent symptom even after remission.
Common Mistakes to Avoid
Saying 'I'm doing okay' or 'The treatment is working' without qualifying current functional limitations
The examiner may record this as minimal symptoms and rate accordingly. Rating is based on current functional impairment, not prognosis.
Instead: Always separate 'the cancer is responding to treatment' from 'I am still significantly disabled by my symptoms and treatment side effects.' Describe your current functional level in detail regardless of treatment response.
Impact: 100% active / post-treatment 100%
Not knowing the date treatment was completed or is anticipated to be completed
The six-month post-treatment mandatory minimum rating period under 38 CFR 4.29 is triggered by the treatment completion date. The examiner must document this date on the DBQ.
Instead: Bring documentation of your treatment start and end dates for surgery, chemotherapy, and radiation. Know these dates before the exam.
Impact: 100% post-treatment period
Failing to mention all treatment modalities received (e.g., forgetting to mention bisphosphonate therapy, targeted therapy, immunotherapy, or clinical trial drugs)
The DBQ specifically captures surgery, radiation, antineoplastic chemotherapy, and other therapeutic treatments. Omitting treatments may result in incomplete documentation of disease severity and treatment burden.
Instead: Make a complete list of every treatment received with dates and outcomes. Include bisphosphonates (e.g., zoledronic acid), denosumab, immunotherapy, targeted therapy, and any clinical trial participation.
Impact: 100% active and post-treatment
Not bringing assistive devices to the exam
The DBQ specifically documents assistive devices (wheelchair, crutches, canes, walker, braces) and their frequency of use. If you leave your cane at home because 'the exam is short,' the examiner may not document it.
Instead: Bring ALL assistive devices you actually use to the exam. Use them as you would normally. The examiner needs to observe your actual functional status.
Impact: All rating levels - affects functional impairment documentation
Not disclosing pathologic fractures because they occurred in the past and 'healed'
Pathologic fractures are a major complication of malignant bone neoplasm and significantly affect the rating. Residual pain, deformity, weakness, and hardware from prior pathologic fractures are all ratable.
Instead: Document all pathologic fractures with dates, locations, treatment received, and current residual symptoms. Bring surgical reports and hardware placement records if available.
Impact: Residuals rating post-treatment
Presenting only as you feel on the day of the exam rather than describing your typical and worst-day functioning
VA exams are meant to capture overall disability, not a single-day snapshot. Veterans often 'push through' for important appointments, presenting better than their average functional state.
Instead: Explicitly tell the examiner: 'Today is not a typical day for me. Let me describe what a typical day and my worst days look like.' Describe your average week and your worst week in concrete, functional terms.
Impact: All rating levels
Failing to discuss secondary conditions caused by the bone cancer or its treatment
Bone cancer and its treatment can cause numerous secondary conditions (peripheral neuropathy, lymphedema, anemia, depression, PTSD from diagnosis, limb loss, radiation necrosis) that may each be separately ratable.
Instead: List every condition that resulted from or was worsened by the bone cancer or its treatment. Ask your VSO whether each should be claimed as a secondary condition.
Impact: Combined rating - secondary conditions can significantly increase overall evaluation
Not clarifying whether the cancer is primary or metastatic/secondary, or failing to identify the primary site if metastatic
The DBQ requires documentation of whether the neoplasm is primary or secondary (metastatic) and, if secondary, the primary cancer site. This affects both rating and nexus documentation.
Instead: Know your diagnosis: is this a primary bone cancer (e.g., osteosarcoma, Ewing sarcoma) or a metastasis from another primary cancer (e.g., prostate cancer metastatic to bone)? Bring pathology reports that clarify this.
Impact: Diagnosis section - affects which DC applies and nexus to service
Prep Checklist
Before Your Exam
Day Of
During the Exam
After the Exam
Your Rights During a C&P Exam
- You have the right to a thorough and adequate C&P examination. The examiner must address all claimed conditions and provide a complete medical opinion. An inadequate exam can be challenged.
- You have the right to request that your C&P exam be recorded in most states. Check your state's recording laws and notify the examiner at the start of the appointment if you intend to record.
- You have the right to bring a support person (family member, VSO representative, or caregiver) to your C&P exam. Confirm the facility's policy in advance, as policies vary.
- You have the right to review the completed DBQ and examiner's report. Request a copy from your VA Regional Office or through eBenefits/VA.gov after the exam.
- You have the right to challenge an inadequate or inaccurate C&P exam by requesting a new exam, submitting a nexus letter from a private physician, or filing a Higher-Level Review or Board Appeal.
- Under 38 CFR 4.29, you have the right to a minimum 100% rating for a period of six months following cessation of surgical, radiation, chemotherapy, or other therapeutic treatment for a malignant neoplasm, followed by a mandatory re-evaluation.
- Under 38 CFR 4.3, when there is reasonable doubt regarding the degree of disability, such doubt must be resolved in the veteran's favor (benefit of the doubt standard).
- You have the right to submit independent medical evidence (private nexus letters, specialist opinions, buddy statements) to supplement the C&P exam findings.
- Under the PACT Act, many veterans with certain cancers may have presumptive service connection based on toxic exposures during military service. Ask your VSO whether your bone cancer may qualify under PACT Act presumptions.
- You have the right to request a higher-level review or file a Board of Veterans' Appeals (BVA) appeal if you disagree with your rating decision. You have one year from the date of the rating decision to file most appeals.
- If you are undergoing active cancer treatment and the exam is scheduled at a time that would be harmful to your health, you may request to reschedule. Document the medical reason with a note from your oncologist.
- You have the right to a VA examination that considers the impact of your condition on employability. If your bone cancer has prevented you from working, discuss Total Disability based on Individual Unemployability (TDIU) with your VSO.
Related Conditions
- Peripheral Neuropathy (Chemotherapy-Induced) Secondary condition chemotherapy agents used to treat bone cancer (e.g., vincristine, cisplatin, paclitaxel) commonly cause peripheral neuropathy affecting hands and feet, which may be separately ratable as a secondary condition.
- Pathologic Fracture Residuals Direct complication malignant bone neoplasms weaken bone structure, leading to pathologic fractures that may result in residual pain, deformity, hardware implantation, and functional loss, all separately ratable.
- Lymphedema Secondary condition surgical treatment for bone cancer involving lymph node dissection or radiation may cause lymphedema in the affected limb, which is separately ratable.
- Amputation / Limb Loss Direct complication limb salvage surgery failure or tumor location may necessitate amputation, rated under separate amputation diagnostic codes in addition to DC 5012.
- Major Depressive Disorder / Adjustment Disorder Secondary condition the psychological burden of a malignant cancer diagnosis and treatment commonly causes or exacerbates depression and anxiety disorders, which may be separately ratable as secondary to the service connected bone cancer.
- Anemia (Treatment-Related) Secondary condition chemotherapy and radiation therapy for bone cancer frequently cause anemia, which may be separately ratable and contributes to the overall disability picture.
- Radiation Necrosis / Radiation-Induced Bone Damage Secondary complication radiation therapy for bone cancer can cause radiation necrosis of bone or adjacent tissues, resulting in pain, fracture risk, and functional loss, separately ratable.
- Metastatic Cancer (Primary Site) If the bone cancer is a secondary (metastatic) malignancy, the primary cancer may itself be a separately ratable service connected condition. Veterans with toxic exposure histories should evaluate the primary malignancy for service connection, including under PACT Act presumptions.
- PTSD / Adjustment Disorder with Anxiety Secondary condition the trauma of cancer diagnosis, treatment, and fear of recurrence can cause or exacerbate PTSD or anxiety disorders, potentially ratable as secondary to service connected bone cancer.
- Cognitive Impairment ('Chemo Brain') Secondary condition chemotherapy associated cognitive impairment (difficulty with memory, concentration, and processing speed) is a recognized complication of antineoplastic chemotherapy and may be ratable as a secondary condition.
Get Personalized C&P Exam Preparation
Upload your medical records for AI-powered prep that maps YOUR symptoms to the exact DBQ fields your examiner will evaluate.
This C&P exam preparation guide is for educational purposes only and does not constitute legal, medical, or claims advice. Always consult with a qualified Veterans Service Organization (VSO) representative or VA-accredited attorney for guidance specific to your claim. Never exaggerate, minimize, or fabricate symptoms during a C&P examination.